PFE: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses. At Pfizer, she has held successive finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group. Immediately before her appointment as Interim Chief Financial Officer, she served as Senior Vice President of Finance for Pfizer’s Global Biopharmaceuticals business since 2022 and Vice President, Finance, Research & Development and Business Office from 2020 to 2022. Ms. Guegan holds a master’s degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor’s degree in Accounting (French DECF). In connection with Ms. Guegan’s election, the Compensation Committee of the Board of Directors of the Company unanimously approved the following compensation arrangements for Ms. Guegan as of the Effective Date: (1) an annual base salary of $1,300,000; and (2) an annual target